Classification of WHO frequency of development of side effects: very often> 1/10 appointments (> 10%); often from> 1/100 to <1/10 of appointments (> 1% and <10%); infrequently from> 1/1000 to <1/100 of prescriptions (> 0.1% and <1%); rarely from> 1/10000 to <1/1000 appointments (> 0.01% and <0.1%); very rarely <1/10000 prescriptions (<0.01%);
the frequency is unknown (the frequency can not be determined from the available data).
Violations of the blood and lymphatic system
Rarely - Lakopenia, thrombocytopenia, hypochromic microcytic anemia in
children.
Rarely agranulocytosis, pancytopenia.
Immune system disorders
Rarely - Hypersensitivity reactions (eg, fever, angioedema, anaphylactic reaction / anaphylactic shock).
Disorders from the metabolism and nutrition Rarely - hyponatremia.
Unknown frequency hypomagnesemia.
Mental Disorders Often -lethargy.
Infrequently - Insomnia.
Rarely - agitation, confusion, depression, hallucinations.
Rarely aggression.
Violations from the nervous system Often - headache.
Infrequently - dizziness, vertigo, paresthesia, drowsiness.
Rarely - a violation of taste.
Disturbance of the organ of vision Rarely blurred vision.
Hearing disorders and labyrinthine disorders
Infrequently - impaired auditory perception, including "ringing in the ears."
Violation of the respiratory system, chest and
the mediastinum
Rarely - bronchospasm.
Disorders from the gastrointestinal tract
Often - diarrhea, constipation, nausea, vomiting, flatulence, abdominal pain.
Rarely - dry mouth, stomatitis, candidiasis of the gastrointestinal tract, microscopic colitis, a taste disorder.
Rarely - pancreatitis.
Disturbances from the liver and bile ducts - Increased activity of "liver" enzymes.
Rarely - Hepatitis (with jaundice or without)
Rarely - hepatic insufficiency, encephalopathy in patients with liver disease.
Disturbances from the skin and subcutaneous tissues infrequently - dermatitis, itching, rash, hives.
Rarely - alopecia, photosensitivity.
Rarely - erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Disturbances from the musculoskeletal and connective tissue Infrequent -fracture of the hip, bones of the wrist and vertebrae.
Rarely - Arthralgia, myalgia.
Rarely - muscle weakness.
Disorders from the kidneys and urinary tract Rarely-interstitial nephritis.
Violations from the genitals and breast cancer Very rarely - gynecomastia.
General disorders and disorders at the site of administration - malaise, peripheral edema.
Rarely - increased sweating.
There have been reports of the formation of gastric glandular cysts during prolonged treatment with proton pump inhibitors (the consequence of inhibiting hydrochloric acid secretion is benign reversible).